HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elizabeth Arden

This article was originally published in The Rose Sheet

Executive Summary

Net sales are expected to grow 8%-9.5% to $900 mil.-$910 mil. in fiscal 2005 (ending June 30), Senior VP-Finance Marcey Becker states during a Banc of America Securities consumer conference in New York City March 16. Earnings per share are anticipated to increase 25%-29% to $1.26-$1.30 in fiscal 2005, Becker adds. Elizabeth Arden will continue to look for fragrance acquisitions to bolster its business, according to CEO Scott Beattie. Firm also has been "quite aggressive at adding new licenses and investing behind our existing licenses," Beattie adds, citing promotions featuring NASCAR driver Jeff Gordon for the Halston fragrance brand as an example. Arden announced the agreement with Gordon last year (1"The Rose Sheet" May 17, 2004, Marketing in Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel